In this Report, we matched a sample of Part B drugs and biological products that had price changes between January 2011 and October 2023 with the FDA’s January 2023 list of drug shortages database. Then we analyzed price changes that occurred before and after the shortage, overall and by select drug characteristics of interest. This analysis is illustrative, it can help identify whether drugs in shortage were particularly likely to have price changes and the characteristics of drugs that were most impacted by shortages and high price increases.
*This content is in the process of Section 508 review. If you need immediate assistance accessing this content, please submit a request to Trinidad Beleche, trinidad.beleche@hhs.gov. Content will be updated pending the outcome of the Section 508 review.